<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author>Дьяконов, В.А.</author>
     <author>Джемилева, Л.У.</author>
     <author>Туктарова, Р.А.</author>
     <author>Макаров, А.А.</author>
     <author>Исламов, И.И.</author>
     <author>Мулюкова, А.Р.</author>
     <author>Джемилев, У.М.</author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2015</year>
    <pub-dates>
     <date>2018-01-11</date>
    </pub-dates>
   </dates>
   <abstract>Two approaches to stereoselective synthesis of steroid 5Z,9Z-dienoic acids were developed, the first one being based on the cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and 1,2-diene cholesterol derivatives on treatment with EtMgBr catalyzed by Cp2TiCl2, while the other involving the synthesis of esters of hydroxy steroids with (5Z,9Z)-tetradeca-5,9-dienedioic acid, prepared in two steps using homo-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran as the key step. High inhibitory activity of the synthesized acids against human topoisomerase I (hTop1) was found.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/609</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/655</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
